Thrombopoietin receptor agonists in refractory immune thrombocytopenia: Differential responses to eltrombopag and romiplostim: A case report and possible explanations

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 6, 2012, Pages 729-732

  Aoki, T ^a   Harada, Y ^a   Matsubara, E ^a   Suzuki, T ^a   Oyama, T ^a   Kasai, M ^a   Uchida, T ^a   Ogura, M ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

eltrombopag; immune thrombocytopenia; romiplostim

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; ELTROMBOPAG; IMMUNOGLOBULIN; PREDNISOLONE; ROMIPLOSTIM;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE THROMBOCYTOPENIA; CASE REPORT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE;

AGED, 80 AND OVER; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; HYDRAZINES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84868358231     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01353.x     Document Type: Article

References (30)

1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010; 115: 168-186.
2. George JN,. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost, 2006; 4: 1664-1672.
3. Kaushansky K,. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost, 1995; 74: 521-525.
4. Kuter DJ,. New thrombopoietic growth factors. Blood, 2007; 109: 4607-4616.
5. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood, 2002; 99: 2599-2602.
6. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ,. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 2001; 98: 3241-3248.
7. Kuter DJ,. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med, 2009; 60: 193-206.
8. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet, 2011; 377: 393-402.
9. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 2008; 371: 395-403.
10. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA,. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 2011; 117: 4190-4207.
11. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med, 2007; 357: 2237-2247.
12. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med, 2006; 355: 1672-1681.
13. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL,. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 2009; 113: 2161-2171.
14. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet, 2009; 373: 641-648.
15. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL,. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood, 2007; 109: 4739-4741.
16. Kumagai Y, Fujita T, Ozaki M, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol, 2007; 47: 1489-1497.
17. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol, 2006; 135: 547-553.
18. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science, 1997; 276: 1696-1699.
19. Wang B, Nichol JL, Sullivan JT,. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther, 2004; 76: 628-638.
20. Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J,. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood, 1995; 86: 4054-4062.
21. Majka M, Ratajczak J, Villaire G, Kubiczek K, Marquez LA, Janowska-Wieczorek A, Ratajczak MZ, et al. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. Exp Hematol, 2002; 30: 751-760.
22. Drachman JG, Millett KM, Kaushansky K,. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem, 1999; 274: 13480-13484.
23. Ezumi Y, Takayama H, Okuma M,. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett, 1995; 374: 48-52.
24. Rojnuckarin P, Drachman JG, Kaushansky K,. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood, 1999; 94: 1273-1282.
25. Broudy VC, Lin NL,. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine, 2004; 25: 52-60.
26. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV,. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood, 2004; 104: 1703-1710.
27. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF,. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest, 2004; 11: 441-450.
28. Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D,. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol, 2011; 51: 842-856.
29. Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E,. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol, 2011; 51: 1403-1417.
30. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M,. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood, 2009; 114: 3748-3756.